All News CKD Corporation

Equities

6407

JP3346800000

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-12 am EDT			5-day change	1st Jan Change
3,270 ^JPY	-1.65%		-1.06%	+28.74%

Jul. 02	Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH	CI
Jun. 26	Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH	Jul. 02	CI
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	Jun. 26	MT
Tan Chong International and Subaru Corporation Initiate Phasing Out Complete Knock Down Business Model	May. 27	MT
Tan Chong International to Shift from CKD Business Model to CBU Sales Model from Japan	May. 24	MT
Jefferies Adjusts CKD'S Price Target to 3,700 Yen From 4,000 Yen, Keeps at Buy	May. 13	MT
AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF
TVS Supply Chain's Supply of CKD Kits to TVS Motor Crosses 500,000	Apr. 11	MT
Final dividend	Mar. 27	FA
Jefferies Upgrades CKD to Buy From Hold, Adjusts Price Target to 4,000 Yen From 2,600 Yen	Mar. 05	MT
Novo Nordisk: EU could authorize Wegovy by April	Feb. 23	CF
Novo Nordisk: EU authorization for Wegovy by April?	Feb. 23	CF
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	Feb. 20	MT
Jefferies Downgrades CKD to Hold From Buy, Adjusts Price Target to 2,600 Yen From 2,300 Yen	Feb. 08	MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	Jan. 31	MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia	Jan. 19	MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia	Jan. 19	MT
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease	Jan. 03	MT
Hansoh Pharma's Three Drugs Added to China’s National Reimbursement Drug List	Dec. 14	MT
AstraZeneca Discontinues Two Phase 3 Evidence Trials of Lokelma in Managing Hyperkalemia	Dec. 01	MT
AstraZeneca: discontinuation of two phase III trials for Lokelma	Dec. 01	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News CKD Corporation

Equities

6407

JP3346800000

All News

Filters